TIL-B may sustain tumor progression by providing lymphotoxin (a survival factor that can induce angiogenesis) and by promoting androgen-independent cancer progression by activating NF-κB and STAT3 pathways [53]. The gene discussed is NFKB1; the disease is cancer.